Genmab — August 2017
-
Tak E L.
-
Det er meget normalt royal, at den mere brede patientpopulation i real life setting giver dårligere resultater end i de mere "kunstige" kliniske studier. Har kun skimmet end del af artiklen, men synes det så meget fornuftigt ud - deres konklussion er mest af alt, at jo tidligere Daratumumab kommer ind i behandlingen des bedre - og det er hvad vi ligeså ser og ønsker.
-
Targeted Oncology, Shaji Kumar, MD, professor of Medicine, Mayo Clinic: "Expert Shares Promising Findings for Long-Term Ixazomib Maintenance in Newly Diagnosed Myeloma" - http://www.targetedonc.com/news/expert-shares-promising-findings-for-longterm-ixazomib-maintenance-in-newly-diagnosed-
myeloma -
-
Fandt denne.. Ninlaro..https://pro.medicin.dk/Medicin/Praeparater/8248
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind